U.S. drug industry group defends price of Gilead hepatitis drug
WASHINGTON (Reuters) - The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C dru...
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/yoHqXltAnzw/story01.htm
No comments:
Post a Comment